Bradykinin B2 Receptor Antagonist off Label Use in Short-Term Prophylaxis in Hereditary Angioedema

Hereditary angioedema type I (HAE-C1-INH) is an inherited disorder characterized by repeated severe angioedema attacks mostly triggered by traumas, emotional stress, increased estrogen levels or surgical procedures, in particular, odontostomatological interventions. Icatibant, a bradykinin B2 recept...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopathology and pharmacology 2014-10, Vol.27 (4), p.653-659
Main Authors: Angeletti, C., Angeletti, P.M., Mastrobuono, F., Pilotti, L., Ciccozzi, A., Guetti, C.
Format: Article
Language:English
Subjects:
Angioedemas, Hereditary - prevention & control
Bradykinin - analogs & derivatives
Bradykinin - therapeutic use
Bradykinin B2 Receptor Antagonists - therapeutic use
Female
Humans
Middle Aged
Off-Label Use
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hereditary angioedema type I (HAE-C1-INH) is an inherited disorder characterized by repeated severe angioedema attacks mostly triggered by traumas, emotional stress, increased estrogen levels or surgical procedures, in particular, odontostomatological interventions. Icatibant, a bradykinin B2 receptor antagonist, has been approved for treatment of HAE attacks. In this paper we describe the “off label” administration of icatibant as short-term prophylaxis of dental extraction in a patient with HAE with the aim of preventing perioperative angioedema attacks. The drug showed an effective and safe profile. Thus, a short-term prophylaxis of angioedema attacks in patients with HAE may be arranged on a multidisciplinary basis, according to the clinical history of each single patients.
ISSN:0394-6320
2058-7384
DOI:10.1177/039463201402700423